PacBio reports Q4 preliminary revenue $39.2M, consensus $40.63M

The company also announced preliminary unaudited revenue for the full year 2024 of $154M. “Though challenging, 2024 was a productive year for PacBio (PACB) as we launched groundbreaking products, strengthened our balance sheet, and made significant progress in reducing cash burn,” said Christian Henry, President and CEO of PacBio. “I believe PacBio is on track to gain market share in 2025 and further enhance our financial position. The early feedback on the Vega System and SPRQ chemistry has been encouraging, and our expansion into the clinical market is beginning to take shape.” Total preliminary unrestricted cash, cash equivalents, and investments balance as of December 31, 2024, is expected to be approximately $390M.